Medical Devices

New data from a major Swedish study reveals SAGA Diagnostics' Pathlight test can predict colorectal cancer recurrence with remarkable accuracy, changing the game.

A new blood test in Western Canada promises to detect 59 cancers early. But with a high price tag and pending approval, it raises critical questions.

LUMA Vision's VERAFEYE™ system combines AI with real-time 4D heart visualization, promising to make complex AFib procedures faster, safer, and more precise.

Following record financial growth, RadNet promotes four executives to accelerate its shift toward proactive, AI-driven healthcare and expand its market dominance.

A new alliance pairs Relation's 'Lab-in-the-Loop' AI with Deerfield's investment might, aiming to fast-track novel drugs for intractable diseases.

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

With a year of record growth and major acquisitions, all eyes are on AHR's Q4 results to see if its strong momentum will carry into 2026.

A landmark trial reveals a new drug combination from BeOne Medicines extends life significantly in advanced stomach cancer, poised to become the new standard.

A new national scholarship from a Las Vegas physician looks beyond grades, using essays to find future doctors committed to ethical service and community care.

A promising antiviral combination for Long COVID gets a major boost, accelerating its path to a pivotal clinical trial led by top researchers.

A new alliance between Medtech Incubator and Leap Distributors promises to bridge the gap between device development and patient access in the U.S.

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

The newly merged Medispend aims to dominate the compliance software market with an expanded suite, deep financial backing, and a string of strategic buys.

With major clinical trials, including a novel approach for Alzheimer's, and key market access wins, MMI's Symani system is poised to redefine microsurgery.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.

STAAR Surgical stockholders rejected a lucrative Alcon merger, betting on the standalone potential of their EVO ICL lenses despite recent financial headwinds.

With its first drug for a rare disease now on the market, Stealth BioTherapeutics bets its future on a deep pipeline targeting mitochondrial dysfunction.

In a strategic move to become a one-stop shop for medical implants, Resonetics acquires pulse generator tech, targeting the booming neuromodulation and BCI markets.

Health Canada greenlights an 8-week pill for acute HCV, a move experts say is a game-changer in the race to eradicate the virus by 2030.

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.